biospecimen banks

CPDR Education and Training

Academic Enrichment

 

Academic Enrichment of CPDR Trainees Through CPDR's Laboratory Meetings, Seminars and Visiting Speakers

The goal of various meetings scheduled on a weekly or monthly basis is::

  1. To enhance the quality of research
  2. To enhance interaction among CPDR researchers and trainees
  3. To follow the progress of trainees in specific research projects
  4. To learn from the experience of colleagues from other institutions
  5. To be current on the most recent discoveries in CaP and other areas of cancer research.

The CPDR supports the visits of distinguished basic science researchers in the field of prostate cancer for two of the four "CPDR Saturday" lectures on a yearly basis (special seminars). Urology residents receive CME credits for their participation in the Saturday meetings. CPDR trainees actively participate in local events such as lectures and workshops at NIH, USUHS and other research institutions in the area. Training of CPDR employees at local educational institutions is strongly encouraged in the areas that will increase their productivity at work.

 

CPDR Saturday Distinguished Speakers

Dr. Warren Heston, Cleveland Clinic (2003)
Dr. William Isaacs, Johns Hopkins University (2003)
Dr. Thomas E. Keane, Univ. South Carolina (2003)
Dr. Michael Kattan, Memorial Sloan-Kettering (2004)
Dr. Johannes Vieweg, Duke University (2004)
Dr. Paul H. Lange, University of Washington (2004)
Dr. John O. Semmes, Eastern Virginia Medical School (2004)
Dr. David E. Crawford, University of Colorado (2005)
Dr. Esther H. Chang, Georgetown University (2005)
Dr. William G. Nelson, Johns Hopkins University (2005)
Dr. Dan Theodorescu, University of Virginia (2006)
Dr. Eric A. Klein, Cleveland Clinic (2006)
Dr. Monica Leibert, AUA Office of Research (2006)
Dr. Dennis K. Watson, University of South Carolina (2006)
Dr. Nancy Dawson, Georgetown University (2007)
Dr. Chawnshang Chang, University of Rochester (2007)
Dr. Dr. Herbert Lepor, New York University Medical Center (2008)
Dr. Angelo De Marzo, Johns Hopkins University (2008)
Dr. Judd W. Moul, Duke University (2009)
Dr. Donald S. Coffey, Johns Hopkins University (2010)
Dr. John Trachtenberg, University of Toronto Ontario, Canada (2010)
Dr. S. Ward Casscells, Former Assistant Secretary of Defense (2011)
Dr. E. Shyam P. Reddy, Georgia Cancer Center for Excellence (2011)
Dr. Fritz H. Schröder, Erasmus Medical Center, the Netherlands (2012)

 

CPDR Thursday Seminar Speakers 2010-2011

Dr. Vasyl Vasko, USUHS
Dr. Deepak Kumar, UDC
Dr. Yang Du, USU
Dr. Masahiro Iwamoto, Thomas Jefferson University, PA
Dr. Suman Kapur, BITS-Pilani, Hyderabad Campus, India
Dr. Jane L. Hudak, WRAMC
Dr. Satya Saxena, Calibrant Biosystems Inc.
Dr. Arun Sreekumar, Medical College of Georgia
Dr. Steve Lincoln, Complete Genomics, Inc.
Dr. Lisa Alvis, Illumina Inc.
Dr. Kathleen S. Kelly, University of Florida
Dr. Vasan Yegnasubramanian, Johns Hopkins University
Dr. Nianxiang (Nick) Zou, AFIP
Dr. David M.Berman, Johns Hopkins Medical Institutions
Dr. Markku Miettinen, NCI, NIH
Dr. Ann Hsing, NCI, NIH
Dr. Matthew l. Freedman, Dana Farber/Harvard Cancer Center MA
Dr. Yan-gao Man, DTRC, HJF
Dr. Ani K. Jaiswal, UMD
Dr. Johnathan Meeks, Johnson & Johnson
Dr. Justin H. Johnson, Edge Bio
Dr. Yun Qiu, Maryland School of Medicine

CURRENT EVENTS


September 29, 2014

Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients

REDWOOD CITY, CA – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence).

Read Full Article

 

WRNMMC UsToo!
Quarterly Guest Speakers

Dr. Valencia Clay
Palliative Care Physician, WRNMMC

Dr. Jerry Waddell
Psychologist and Program Director of the Palliative Care Service, WRNMMC

Presentation: "Quality of Life in Disease Progression"

Free and no registration required.

Date: Thursday, 6 November 2014
Time: 7-8:30 PM
Location: America Building, 2nd floor, Room 2525
(above the lab/pharmacy) and Fort Belvoir Community Hospital
(Oaks Pavilion, 1st floor, Room 332)
by videoteleconference.
Contact: COL (ret) Jane Hudak for more information at 301-319-2918 or
jane.l.hudak.ctr@health.mil

Read the NOVEMEBR 2014 Newsletter